• Citer

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study.

par Adès, Lionel;Boehrer, S;Prebet, Thomas;Beyne-Rauzy, Odile;Legros, Laurence;Ravoet, Christophe;Dreyfus, François;Stamatoullas, Aspasia;Chaury, Marie Pierre;Delaunay, Jacques;Laurent, Gauthier ;Vey, Norbert;Burcheri, Sara;Mbida, Rose-Marie;Hoarau, Natacha;Gardin, C;Fenaux, Pierre
Référence Blood, 113, 17, page (3947-3952)
Publication Publié, 2009-04

Article révisé par les pairs

• Détails
• Contenu

Titre:	Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study.
Auteur:	Adès, Lionel; Boehrer, S; Prebet, Thomas; Beyne-Rauzy, Odile; Legros, Laurence; Ravoet, Christophe; Dreyfus, François; Stamatoullas, Aspasia; Chaury, Marie Pierre; Delaunay, Jacques; Laurent, Gauthier; Vey, Norbert; Burcheri, Sara; Mbida, Rose-Marie; Hoarau, Natacha; Gardin, C; Fenaux, Pierre
Informations sur la publication:	Blood, 113, 17, page (3947-3952)
Statut de publication:	Publié, 2009-04
Sujet CREF:	Cancérologie
MeSH keywords:	Adult
	Aged
	Aged, 80 and over
	Chromosome Deletion
	Chromosomes, Human -- genetics
	Female
	Humans
	Male
	Middle Aged
	Myelodysplastic Syndromes -- drug therapy -- genetics -- pathology
	Prognosis
	Risk Factors
	Survival Rate
	Thalidomide -- adverse effects -- analogs & derivatives -- pharmacology -- therapeutic use
	Treatment Outcome
Note générale:	Clinical Trial, Phase II
	Journal Article
Langue:	Anglais
Identificateurs:	urn:issn:0006-4971
	info:doi/10.1182/blood-2008-08-175778
	info:pii/blood-2008-08-175778
	info:pmid/18987358